First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting

被引：124

作者：

Molckovsky, Andrea ^{[1
]}

Siu, Lillian L. ^{[1
]}

机构：

[1] Univ Toronto, Princess Margaret Hosp, Div Hematol & Med Oncol, Toronto, ON, Canada

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2008年 / 1卷 / 1期

关键词：

D O I：

10.1186/1756-8722-1-20

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This review summarizes phase I trial results of 11 drugs presented at the American Society of Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322, CVX-045, GDC-0449, GRN163L, LY2181308, PF-00562271, RAV12, RTA 402, XL765, and the survivin vaccine.

引用

页数：9

共 37 条

[31] First human dose study evaluating safety and pharmacokinetics of LY2181308, an antisense oligonucleotide designed to inhibit survivin [J].

Talbot, D. C. ;

Davies, J. ;

Callies, S. ;

Andre, V. ;

Lahn, M. ;

Ang, J. ;

De Bono, J. S. ;

Ranson, M. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[32] Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes [J].

Yates, Melinda S. ;

Tauchi, Masafumi ;

Katsuoka, Fumiki ;

Flanders, Kathleen C. ;

Liby, Karen T. ;

Honda, Tadashi ;

Gribble, Gordon W. ;

Johnson, Delinda A. ;

Johnson, Jeffrey A. ;

Burton, Neal C. ;

Guilarte, Tomas R. ;

Yamamoto, Masayuki ;

Sporn, Michael B. ;

Kensler, Thomas W. .

MOLECULAR CANCER THERAPEUTICS, 2007, 6 (01) :154-162

[33]

STUDY EXPT CHEMOTHER

[34]

STUDY GDC 0449 MAINT

[35]

CT 322 TREATING PATI

[36]

RANDOMIZED MULTIDOSE

[37]

STUDY SYSTEMIC HEDGE

← 1 2 3 4 →